Abstract
The current increase in the number of microbes resistant to antibacterial or antifungal agents represents a potential crisis in human and veterinary medicine. Some believe that we are entering a postantibiotic era where most antibiotics no longer will be efficacious. Therefore, it is important that new antibiotics be developed. However, because of the potential for cross-resistance, new targets for the discovery of antibiotics are needed particularly where resistance does not currently exist. The results obtained from the sequencing of genomes from pathogenic bacterial and fungal microbes provide an opportunity to ameliorate this problem. Genomic sequence data can be used to identify new genes that could be used as targets for new antibiotic discoveries. Viable new target genes might represent those that are widely distributed among pathogens or that have homologs and are essential for the viability of the organism. Chemical compounds that attack such targets would be expected to have classical antibiotic activities. Less widely distributed genes still could be valuable targets for narrow spectrum antibiotics. While many of these genes will have known or putative functions based on DNA sequence homology, the most interesting genes are the newly discovered genes with unknown functions. In this paper, it is suggested that novel, non-traditional targets also will be found through the analysis of genome sequences: those that are involved in disease pathogenesis and those that are involved in adaptation and growth in infection sites. The advantage of the non-classical targets is that targeting these sites may not result in the same degree of selective pressure that encourages resistance, and these could have a longer therapeutic life time.
Keywords: antibacterial, antifungal, genomics
Current Pharmaceutical Design
Title: Genomics and the Prospects for the Discovery of New Targets for Antibacterial and Antifungal Agents
Volume: 8 Issue: 13
Author(s): Richard E. Isaacson
Affiliation:
Keywords: antibacterial, antifungal, genomics
Abstract: The current increase in the number of microbes resistant to antibacterial or antifungal agents represents a potential crisis in human and veterinary medicine. Some believe that we are entering a postantibiotic era where most antibiotics no longer will be efficacious. Therefore, it is important that new antibiotics be developed. However, because of the potential for cross-resistance, new targets for the discovery of antibiotics are needed particularly where resistance does not currently exist. The results obtained from the sequencing of genomes from pathogenic bacterial and fungal microbes provide an opportunity to ameliorate this problem. Genomic sequence data can be used to identify new genes that could be used as targets for new antibiotic discoveries. Viable new target genes might represent those that are widely distributed among pathogens or that have homologs and are essential for the viability of the organism. Chemical compounds that attack such targets would be expected to have classical antibiotic activities. Less widely distributed genes still could be valuable targets for narrow spectrum antibiotics. While many of these genes will have known or putative functions based on DNA sequence homology, the most interesting genes are the newly discovered genes with unknown functions. In this paper, it is suggested that novel, non-traditional targets also will be found through the analysis of genome sequences: those that are involved in disease pathogenesis and those that are involved in adaptation and growth in infection sites. The advantage of the non-classical targets is that targeting these sites may not result in the same degree of selective pressure that encourages resistance, and these could have a longer therapeutic life time.
Export Options
About this article
Cite this article as:
Isaacson E. Richard, Genomics and the Prospects for the Discovery of New Targets for Antibacterial and Antifungal Agents, Current Pharmaceutical Design 2002; 8 (13) . https://dx.doi.org/10.2174/1381612023394764
DOI https://dx.doi.org/10.2174/1381612023394764 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Artificial Neural Networks to Optimize Formulation Components of a Fixed- Dose Combination of Rifampicin, Isoniazid and Pyrazinamide in a Microemulsion
Current Drug Discovery Technologies Chalcones and Chromones in Copper-Catalyzed Azide–Alkyne Cycloadditions (CuAAC)
Current Organic Chemistry HIV-1 Prophylactic Vaccine Trials in Thailand
Current HIV Research The Site-specific Protonation Constants of Spectinomycin, Characterized by <sup>1</sup>H and <sup>15</sup>N NMR Methods
Current Pharmaceutical Analysis Anticancer Activities of New N-hetaryl-2-cyanoacetamide Derivatives Incorporating 4,5,6,7-Tetrahydrobenzo[b]thiophene Moiety
Anti-Cancer Agents in Medicinal Chemistry Gelrite® Microgels for Sustained Oral Drug Delivery-Formulation and Evaluation
Current Drug Delivery Editorial [Hot Topic: Fighting Malaria in the 21st Century (Executive Editor: Pedro L. Alonso) ]
Current Molecular Medicine Editorial [Hot topic: Structural Genomics (Executive Editor: Yu Wai Chen)]
Infectious Disorders - Drug Targets From Body Art to Anticancer Activities: Perspectives on Medicinal Properties of Henna
Current Drug Targets Targeting DNA Gyrase to Combat Mycobacterium tuberculosis: An Update
Current Topics in Medicinal Chemistry Cancer Imaging Agents for Positron Emission Tomography: Beyond FDG
Current Medical Imaging Role of Type I Cytokines in Host Defense Against Mycobacterium avium Infection
Current Pharmaceutical Design Carbonic Anhydrase Inhibition/Activation: Trip of a Scientist Around the World in the Search of Novel Chemotypes and Drug Targets
Current Pharmaceutical Design The Effect of Pyrroloquinoline Quinone on Apoptosis and Autophagy in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets HIV Drug Resistance Interpreted by Cumulative Versus Last Genotypes in HIV-Infected Patients with Multiple Treatment Failures
Current HIV Research Effects of Alcohol in the Lung
Current Respiratory Medicine Reviews Bactericidal and Hemolytic Activities of Synthetic Peptides Derived from Granulysin
Protein & Peptide Letters Metabolite Concentration as a Criterion for Antibacterial Discovery
Current Computer-Aided Drug Design Dendritic Cells and Macrophages: Same Receptors but Different Functions
Current Immunology Reviews (Discontinued) Polyfunctional Antibiotics Affecting Bacterial Membrane Dynamics
Anti-Infective Agents in Medicinal Chemistry